Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS.~* Patient meets the FDA-approved indication for Atezolizumab treatment in NSCLC.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.~* Ability to provide informed consent.~* Adequate hematological, liver and kidney function.~* Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration.~Key Exclusion Criteria:~* Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration~* Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation).~* Pregnant women.~* Nursing women.~* Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment.~* Allergy to measles vaccine or history of severe reaction to prior measles vaccination.~* History of organ transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MV-NIS and Atezolizumab (Type: EXPERIMENTAL): MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).